Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.

Megan N. Thobe, Richard A. Walgren, Kelly M. Credille et al.|Cancer Research|2013

Cited by 3